Edison’s technology centers on a unique understanding of the physical chemistry and biochemistry of reversible electron transfer reactions, commonly referred to as redox. Redox chemistry underlies how cells make and regulate energy metabolism. Edison has proprietary assays and know-how that facilitate the modeling of redox defects in biological systems, accelerating the discovery and optimization of redox-directed drugs. In partnership with our clinical investigator team, Edison has devised enabling translational assays to bridge laboratory models with non-invasive therapeutic and disease metrics.
EPI-743 is an orally absorbed small molecule that readily crosses into the central nervous system. It works by targeting the enzyme NADPH quinone oxidoreductase 1 (NQO1). Its mode of action is to synchronize energy generation in mitochondria with the need to counter cellular redox stress1.
EPI-A0001 is an orally absorbed small molecule. EPI-A0001 has completed phase 1A and phase 1B studies in healthy volunteers and phase 2 in the mitochondrial disease Friedreich's ataxia.